Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$186.05 +1.2%	$192.18	$137.23 ▼ $212.71	$288.54B	0.26	2.63 million shs	461,545 shs
BIIB Biogen	$191.64 -0.1%	$185.29	$121.05 ▼ $205.97	$28.29B	0.19	1.30 million shs	271,959 shs
LLY Eli Lilly and Company	$1,012.70 +2.5%	$940.00	$623.78 ▼ $1,133.95	$953.70B	0.48	3.16 million shs	1.30 million shs
MRK Merck & Co., Inc.	$114.80 +2.0%	$115.94	$75.40 ▼ $125.14	$283.52B	0.18	10.86 million shs	1.71 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+1.29%	+1.13%	-10.27%	-12.18%	+33.68%
BIIB Biogen	-0.54%	-3.05%	+8.21%	-1.90%	+52.81%
LLY Eli Lilly and Company	-1.64%	+2.37%	+6.67%	-4.54%	+30.58%
MRK Merck & Co., Inc.	+1.14%	+1.04%	-5.35%	-7.32%	+48.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$186.05 +1.2%	$192.18	$137.23 ▼ $212.71	$288.54B	0.26	2.63 million shs	461,545 shs
BIIB Biogen	$191.64 -0.1%	$185.29	$121.05 ▼ $205.97	$28.29B	0.19	1.30 million shs	271,959 shs
LLY Eli Lilly and Company	$1,012.70 +2.5%	$940.00	$623.78 ▼ $1,133.95	$953.70B	0.48	3.16 million shs	1.30 million shs
MRK Merck & Co., Inc.	$114.80 +2.0%	$115.94	$75.40 ▼ $125.14	$283.52B	0.18	10.86 million shs	1.71 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+1.29%	+1.13%	-10.27%	-12.18%	+33.68%
BIIB Biogen	-0.54%	-3.05%	+8.21%	-1.90%	+52.81%
LLY Eli Lilly and Company	-1.64%	+2.37%	+6.67%	-4.54%	+30.58%
MRK Merck & Co., Inc.	+1.14%	+1.04%	-5.35%	-7.32%	+48.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.85	Moderate Buy	$205.33	10.37% Upside
BIIB Biogen	2.52	Moderate Buy	$215.62	12.51% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,218.33	20.31% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	11.66% Upside

Current Analyst Ratings Breakdown

Latest BIIB, MRK, LLY, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/15/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$214.00 ➝ $225.00
5/15/2026	BIIB Biogen	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
5/14/2026	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $300.00
5/13/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/7/2026	LLY Eli Lilly and Company	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$880.00 ➝ $900.00
5/6/2026	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$125.00
5/5/2026	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,183.00
5/4/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$58.74B	4.91	$13.24 per share	14.05	$31.41 per share	5.92
BIIB Biogen	$9.89B	2.86	$22.49 per share	8.52	$124.45 per share	1.54
LLY Eli Lilly and Company	$72.25B	13.20	$25.33 per share	39.98	$28.07 per share	36.08
MRK Merck & Co., Inc.	$65.01B	4.36	$11.77 per share	9.75	$21.22 per share	5.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.66	27.93	16.11	1.49	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	20.56	11.57	1.70	13.81%	12.83%	8.01%	7/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	35.98	22.90	1.09	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	32.34	11.74	2.51	13.59%	27.55%	10.73%	8/4/2026 (Estimated)

Latest BIIB, MRK, LLY, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.33%	+2.30%	65.17%	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.68%	+15.18%	24.58%	11 Years
MRK Merck & Co., Inc.	$3.40	2.96%	+5.75%	95.77%	14 Years

Latest BIIB, MRK, LLY, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.52	0.91	0.71
BIIB Biogen	0.34	3.06	2.41
LLY Eli Lilly and Company	1.26	1.50	1.10
MRK Merck & Co., Inc.	1.02	1.30	1.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
BIIB Biogen	87.93%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
BIIB Biogen	0.25%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable

BIIB, MRK, LLY, and AZN Headlines

Recent News About These Companies

Arketi Group Expands Capabilities and Footprint, Welcomes Braithwaite Communications to Digital Marketing and PR Platform

2 hours ago | finance.yahoo.com

Handelsbanken Fonder AB Boosts Stock Holdings in Merck & Co., Inc. $MRK

May 19 at 4:22 AM | marketbeat.com

HighTower Advisors LLC Sells 50,990 Shares of Merck & Co., Inc. $MRK

May 19 at 4:05 AM | marketbeat.com

Gabelli Funds LLC Cuts Holdings in Merck & Co., Inc. $MRK

May 19 at 3:46 AM | marketbeat.com

Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda

May 18 at 8:58 AM | proactiveinvestors.com

7 Healthcare AI Stocks Under $50 With Huge Upside Potential

May 18 at 7:35 AM | 247wallst.com

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

May 18 at 7:28 AM | barrons.com

Merck's endometrial cancer drug meets late-stage trial goals

May 18 at 6:51 AM | reuters.com

L & S Advisors Inc Increases Stake in Merck & Co., Inc. $MRK

May 17 at 6:41 AM | marketbeat.com

Canada Post Corp Registered Pension Plan Acquires 35,631 Shares of Merck & Co., Inc. $MRK

May 17 at 4:29 AM | marketbeat.com

2 Cash-Producing Stocks to Research Further and 1 Facing Challenges

May 17 at 3:47 AM | finance.yahoo.com

A Futuristic Synthesis Indeed

May 16 at 8:30 AM | seekingalpha.com

Financial Security Advisor Inc. Raises Holdings in Merck & Co., Inc. $MRK

May 16 at 6:29 AM | marketbeat.com

Lockheed Martin Investment Management Co. Has $9.87 Million Stock Holdings in Merck & Co., Inc. $MRK

May 16 at 6:11 AM | marketbeat.com

Merck & Co., Inc. $MRK Shares Acquired by Convergence Investment Partners LLC

May 16 at 4:31 AM | marketbeat.com

Merck & Co., Inc. $MRK Stake Reduced by ANTIPODES PARTNERS Ltd

May 16 at 3:07 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Lowered to Hold Rating by Wall Street Zen

May 16 at 1:55 AM | americanbankingnews.com

Merck & Co., Inc. $MRK Stock Holdings Increased by Phoenix Financial Ltd.

May 15, 2026 | marketbeat.com

Thrivent Financial for Lutherans Raises Stock Holdings in Merck & Co., Inc. $MRK

May 15, 2026 | marketbeat.com

Merck ASCO 2026 Data Sheds Light On Oncology Outlook And Valuation

May 15, 2026 | finance.yahoo.com

Bessemer Group Inc. Increases Holdings in Merck & Co., Inc. $MRK

May 15, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BIIB, MRK, LLY, and AZN Company Descriptions

Astrazeneca NYSE:AZN

$186.05 +2.13 (+1.16%)

As of 11:55 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Biogen NASDAQ:BIIB

$191.64 -0.28 (-0.14%)

As of 11:55 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company NYSE:LLY

$1,012.70 +24.61 (+2.49%)

As of 11:55 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$114.80 +2.24 (+1.99%)

As of 11:55 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, MRK, LLY, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, MRK, LLY, and AZN Earnings

Compare Dividends

Latest BIIB, MRK, LLY, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, MRK, LLY, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BIIB, MRK, LLY, and AZN Company Descriptions

Astrazeneca NYSE:AZN

Biogen NASDAQ:BIIB

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools